A Prospective, Multicentre, Randomized, Open Label, Blinded Endpoint, Phase 3 Trial to Assess the Safety and Efficacy of Prophylactic TicagrelOr with Acetylsalicylic Acid versus CLopidogrel with Acetylsalicylic Acid in the Development of Cerebrovascular EMbolic Events during Transcatheter Aortic Valve Implantation (TAVI) OperationS

Trial Profile

A Prospective, Multicentre, Randomized, Open Label, Blinded Endpoint, Phase 3 Trial to Assess the Safety and Efficacy of Prophylactic TicagrelOr with Acetylsalicylic Acid versus CLopidogrel with Acetylsalicylic Acid in the Development of Cerebrovascular EMbolic Events during Transcatheter Aortic Valve Implantation (TAVI) OperationS

Recruiting
Phase of Trial: Phase III

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Ticagrelor (Primary) ; Clopidogrel
  • Indications Ischaemic heart disorders
  • Focus Therapeutic Use
  • Acronyms PTOLEMAIOS
  • Most Recent Events

    • 22 Feb 2017 Status changed from not yet recruiting to recruiting.
    • 19 Jul 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top